10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA's Clinical Studies Network
Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics providing broader and more durable protection against current and future COVID-19 viral strains
https://finance.yahoo.com/news/geovax-receives-barda-project-nextgen-110000120.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.